Non-CME/CE
Pulmonology
Discuss the ongoing burden and shifting epidemiology of pneumococcal disease in adults; Review the robust clinical trial program for an option to help address IPD in adults; Highlight the 2024 CDC recommendations for adult pneumococcal disease
Merck & Co., Inc.